About: Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Sector: Healthcare
Industry: Biotechnology
Latest price: $30.92 (-3.50%)
IMVT NASDAQ Immunovant Inc
Immunovant Inc share price
IMVT price activity
Último preço
$ 30,920
Variação (24h)
-1,12 USD (-3,50%)
Volume
160.12K
Volume (média 4 sem.)
-
Abertura
$ 31,40
Variação do dia
$ 30,70 - $ 31,50
Fechamento anterior
$ 32,04
Último negócio
08 Oct, 2:08 pm GMT+0
Atrasado
08 Oct, 2:08 pm GMT+0
IMVT price performance
Atrasado
08 Oct, 2:08 pm GMT+0
quote.marketSignals